MX370792B - Composiciones para usarse en el tratamiento de cáncer. - Google Patents

Composiciones para usarse en el tratamiento de cáncer.

Info

Publication number
MX370792B
MX370792B MX2015015518A MX2015015518A MX370792B MX 370792 B MX370792 B MX 370792B MX 2015015518 A MX2015015518 A MX 2015015518A MX 2015015518 A MX2015015518 A MX 2015015518A MX 370792 B MX370792 B MX 370792B
Authority
MX
Mexico
Prior art keywords
cancer
treatment
compositions
methods
omomyc
Prior art date
Application number
MX2015015518A
Other languages
English (en)
Other versions
MX2015015518A (es
Inventor
Soucek Laura
Beaulieu Marie-Eve
Original Assignee
Fundacio Privada Inst D´Investigacio Oncologica De Vall Hebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Privada Inst D´Investigacio Oncologica De Vall Hebron filed Critical Fundacio Privada Inst D´Investigacio Oncologica De Vall Hebron
Publication of MX2015015518A publication Critical patent/MX2015015518A/es
Publication of MX370792B publication Critical patent/MX370792B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La invención se refiere a un polipéptido que consiste en la SEQ ID NO: 1, o una variante funcionalmente equivalente del mismo, que tiene un grado de identidad con respecto a la SEQ ID NO: 1 mayor que 70%, en donde la variante funcionalmente equivalentemente es un polipéptido resultante de la inserción o de la adición de un aminoácido y/o de la eliminación de uno o más aminoácidos y/o de la sustitución conservativa de uno o más aminoácidos con respecto al polipéptido de la SEQ ID NO: 1 y en donde la variante funcionalmente equivalente del mismo puede dimerizar con Myc e inhibir su actividad una vez que se encuentra en el núcleo, siendo capaz de trastocarse a través de la membrana celular y a través de la envoltura nuclear, para usarse en medicina, en donde el polipéptido o la variante funcionalmente equivalente del mismo es para ser administrable.
MX2015015518A 2013-05-07 2014-05-07 Composiciones para usarse en el tratamiento de cáncer. MX370792B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20130382167 EP2801370A1 (en) 2013-05-07 2013-05-07 Methods and compositions for the treatment of cancer
PCT/EP2014/059315 WO2014180889A1 (en) 2013-05-07 2014-05-07 Methods and compositions for the treatment of cancer

Publications (2)

Publication Number Publication Date
MX2015015518A MX2015015518A (es) 2016-07-21
MX370792B true MX370792B (es) 2020-01-08

Family

ID=48366303

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015518A MX370792B (es) 2013-05-07 2014-05-07 Composiciones para usarse en el tratamiento de cáncer.

Country Status (25)

Country Link
US (2) US10370434B2 (es)
EP (4) EP2801370A1 (es)
JP (2) JP6722103B2 (es)
KR (1) KR102324116B1 (es)
CN (1) CN105378084B (es)
AU (1) AU2014264642B2 (es)
BR (2) BR122020017819B1 (es)
CA (1) CA2911863A1 (es)
CY (1) CY1121849T1 (es)
DK (1) DK2994533T3 (es)
EA (2) EA035463B1 (es)
ES (1) ES2733515T3 (es)
HK (2) HK1219756A1 (es)
HR (1) HRP20191330T1 (es)
HU (1) HUE045615T2 (es)
IL (2) IL242483B (es)
LT (1) LT2994533T (es)
ME (1) ME03509B (es)
MX (1) MX370792B (es)
PL (1) PL2994533T3 (es)
PT (1) PT2994533T (es)
RS (1) RS59276B1 (es)
SG (2) SG10201709101VA (es)
SI (1) SI2994533T1 (es)
WO (1) WO2014180889A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2801370A1 (en) 2013-05-07 2014-11-12 Fundació Privada Institut d'Investigació Oncològica de Vall Hebron Methods and compositions for the treatment of cancer
EP3411387A4 (en) 2016-02-03 2019-12-04 Kennesaw State University Research And Services Foundation Inc. SIGNAL MOLECULES USEFUL AS CELL PENETRATION AGENTS
WO2017190061A1 (en) * 2016-04-29 2017-11-02 The University Of Chicago Synthetic dna binding domain peptides and uses thereof
EP3269734A1 (en) * 2016-07-15 2018-01-17 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Methods and compositions for the treatment of cancer
CN106591335A (zh) * 2016-11-08 2017-04-26 安徽省农业科学院水稻研究所 一种密码子植物化改造的LbCpf1基因及其应用
KR20200052350A (ko) * 2017-09-08 2020-05-14 아이디피 디스커버리 파마, 에스.엘. 다발성 골수종의 새로운 치료
SG11202004861UA (en) * 2017-11-29 2020-06-29 Agency Science Tech & Res Chimeric molecule for targeting c-myc in cells
WO2019199803A1 (en) * 2018-04-09 2019-10-17 Board Of Regents, The University Of Texas System Therapeutic targeting of oncogenes using exosomes
CA3126544A1 (en) * 2019-01-12 2020-07-16 The Methodist Hospital Self-assembled peptide nanoparticle and use thereof
AU2020242284A1 (en) 2019-03-19 2021-09-16 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy for the treatment of cancer
TWI829893B (zh) * 2019-03-19 2024-01-21 瓦爾希伯倫私人腫瘤研究基金會 診斷肺癌的方法
KR102221227B1 (ko) 2019-05-07 2021-03-03 김영화 공급자 연동과 다국어 지원 기능을 구비한 쇼핑몰 플랫폼 제공 장치 및 그 방법
US20220307013A1 (en) * 2019-08-30 2022-09-29 The Regents Of The University Of California Gene fragment overexpression screening methodologies, and uses thereof
CN115925975A (zh) * 2022-08-03 2023-04-07 山东大学 一种靶向肿瘤干细胞的car-mφ体内外编辑制备方法以及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US5322801A (en) 1990-04-19 1994-06-21 The General Hospital Corporation Protein partner screening assays and uses thereof
WO1993019176A1 (en) 1992-03-23 1993-09-30 Imperial Cancer Research Technology Limited Leucine zippers
EP1342781A1 (en) * 2002-03-09 2003-09-10 ARTEMIS Pharmaceuticals GmbH Recombinase fusion protein with enhanced cellular uptake
GB0413730D0 (en) * 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
AU2010295646B2 (en) * 2009-09-15 2016-02-11 Ellipses Pharma Limited Treatment of cancer
DE102009052866A1 (de) 2009-11-13 2011-05-19 Bizerba Gmbh & Co. Kg Schneidemaschine
EP2544686A4 (en) 2010-02-05 2013-06-26 Whitehead Biomedical Inst COMBINED METHODS FOR THE TREATMENT OF DISEASES
EP2579899B1 (en) * 2010-06-14 2017-03-15 F. Hoffmann-La Roche AG Cell-penetrating peptides and uses thereof
US9241920B2 (en) * 2011-10-27 2016-01-26 New York University Inhibition of c-Myc ubiquitination to prevent cancer initiation and progression
EP2801370A1 (en) 2013-05-07 2014-11-12 Fundació Privada Institut d'Investigació Oncològica de Vall Hebron Methods and compositions for the treatment of cancer

Also Published As

Publication number Publication date
RS59276B1 (sr) 2019-10-31
JP6722103B2 (ja) 2020-07-15
US10370434B2 (en) 2019-08-06
EA202090683A3 (ru) 2020-09-30
US11339205B2 (en) 2022-05-24
HK1251494A1 (zh) 2019-02-01
IL273090B (en) 2022-06-01
AU2014264642A1 (en) 2015-11-19
HRP20191330T1 (hr) 2019-10-18
BR112015028115B1 (pt) 2023-11-21
JP2016520056A (ja) 2016-07-11
LT2994533T (lt) 2019-08-12
PT2994533T (pt) 2019-08-05
CN105378084B (zh) 2019-07-05
EA201690159A1 (ru) 2016-05-31
EP2801370A1 (en) 2014-11-12
JP2019147792A (ja) 2019-09-05
BR112015028115A2 (pt) 2017-10-17
ES2733515T3 (es) 2019-11-29
IL242483B (en) 2020-03-31
WO2014180889A8 (en) 2015-06-18
EP2994533B1 (en) 2019-05-01
KR102324116B1 (ko) 2021-11-11
JP6790148B2 (ja) 2020-11-25
WO2014180889A1 (en) 2014-11-13
EP3338789A1 (en) 2018-06-27
HK1219756A1 (zh) 2017-04-13
EP3545966A1 (en) 2019-10-02
SI2994533T1 (sl) 2019-09-30
US20160122415A1 (en) 2016-05-05
MX2015015518A (es) 2016-07-21
ME03509B (me) 2020-04-20
HUE045615T2 (hu) 2020-01-28
BR122020017819B1 (pt) 2023-11-21
CY1121849T1 (el) 2020-07-31
US20190382468A1 (en) 2019-12-19
AU2014264642B2 (en) 2020-09-17
DK2994533T3 (da) 2019-07-01
CA2911863A1 (en) 2014-11-13
EA035463B1 (ru) 2020-06-19
IL273090A (en) 2020-04-30
PL2994533T3 (pl) 2020-03-31
CN105378084A (zh) 2016-03-02
KR20160013058A (ko) 2016-02-03
EA202090683A2 (ru) 2020-06-30
SG11201509131VA (en) 2015-12-30
SG10201709101VA (en) 2017-12-28
EP2994533A1 (en) 2016-03-16

Similar Documents

Publication Publication Date Title
MX2015015518A (es) Metodos y composiciones para el tratamiento del cancer.
MX2021006531A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
CA2956871C (en) Compounds active towards bromodomains
TW201613901A (en) New compounds
MX2016008131A (es) Compuestos heterociclos biciclicos y sus usos en terapia.
PH12014501991B1 (en) Phenicol antibacterials
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MA39710A (fr) Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
MX2016003293A (es) Metodos y composiciones para el tratamiento de una infeccion por clamidia y enfermedades y trastornos relacionados.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
PH12015502564B1 (en) Pyridone derivatives for the treatment of viral infections and further diseases
MX370436B (es) Composicion farmaceutica para usarse en el tratamiento o la prevencion de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugia de derivacion gastrica.
EP3235808A4 (en) Modified taurine, and pharmaceutical composition for preventing or treating metabolic diseases containing same
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
MX360040B (es) Nuevo agente antibacteriano derivado de florfenicol unido a sulfoximina y el uso del mismo en el tratamiento de infecciones bacterianas en ganado vacuno.
MX2018004532A (es) Combinacion de trazodona y gabapentina para el tratamiento de dolor.
MX2017001512A (es) Compuestos activos hacia bromodominios.

Legal Events

Date Code Title Description
FG Grant or registration